Tirzepatide itself doesn't determine your sagging skin outcome
The cohort comprised 1479 participants, with a mean age of 64.6 years
CASE REPORT A 29-year-old female, who had no significant past medical or surgical history, presented to the emergency department (ED) with epigastric pain associated and vomiting 34 times per day which started 2 days prior to the ED visit
This makes retatrutide a GLP-1/GIP/glucagon triple agonist, and the first molecule of its kind to reach advanced clinical trials
The actions of GLP-1 and GIP on glucagon secretion are different, since GLP-1 suppresses glucagon [63] during hyperglycemia [64,65,66], but not at a normal fasting plasma glucose concentration [65]
The compromise position adopted by the European Council in June 2025 incorporated 10 years of orphan market exclusivity, the same as under current legislation, and an improvement on the nine years of baseline orphan market exclusivity proposed by both the Commission and Parliament